Elena has had a myocardial infarction and has type two diabetes. She is prescribed a high-intensity statin, but a prescription does not establish actual use or tolerance. Review the medicine, access, missed doses and current lipid response before choosing the next treatment. Do not assume statin intolerance from the information given.

Use CLEAR Outcomes to practice reading an endpoint. It enrolled thirteen thousand nine hundred seventy statin-intolerant patients with, or at high risk for, cardiovascular disease. The primary composite event occurred in eleven point seven percent with bempedoic acid and thirteen point three percent with placebo. The absolute difference was one point six percentage points over a median follow-up of forty point six months. That is a trial result, not Elena's predicted personal benefit.

Benefit and safety belong in the same discussion. Gout and gallstones were more frequent with bempedoic acid in CLEAR Outcomes. Review the current label, relevant history, interactions, other treatment options and access. The trial's population matters: Elena should not be assigned to a statin-intolerant treatment pathway without first confirming her experience.

Apply the same discipline to new therapies. A lower biomarker does not by itself prove fewer clinical events. Identify the population, comparator, clinical endpoint, absolute result and uncertainty, then check regulatory status. Investigational treatment is not established care. For Elena's handoff, justify the next secondary-prevention decision and name who will check the response.